CTBP2 and ovarian serous cystadenocarcinoma: Interesting, patients with CtBP2’s genetic alternation were significantly associated with longer overall survival time (median time: 61.67 months, log rank test, P value: 3.198e−4, n = 72) than unaltered patients (median time: 44.48 months, n = 1561) in ovarian serous cystadenocarcinoma patients during 10-year survival period (Fig. S4B).